New hope: hepatitis c drugs after liver cancer treatment
NCT ID NCT02771405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 weeks after treatment, and to check for any cancer return.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sofosbuvir, Ribavirin, Simeprevir, Daclatasvir, Ledipasvir
- What this could lead to
- If successful, this could show that treating hepatitis C after liver cancer treatment reduces cancer recurrence and improves long-term outcomes.
- What could go wrong
- This is a completed Phase 3 trial, but results may not apply to all patients. There is a risk of virologic failure or cancer recurrence despite treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amr Maged
Cairo, 11441, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?